Loading…

Align TechnologyALGNCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of Invisalign clear dental aligners and iTero intraoral scanners for orthodontic and general dentistry practices.

Momentum strong 69
Mkt cap
$11.6B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$194M
20-day average traded
Fwd P/E
13.8×
forward earnings
ROIC−WACC
+5.7 pp
WACC 13.6%
Hurdle
+3 pp
Req g minus delivered
Next earnings
77 days
3 Feb 2027
Close · USD$163.96
1D+0.3%
1W-4.7%
1M+8.9%
3M+3.2%
6M+0.3%
YTD+5.0%
1Y+23.6%
ATR %3.5%
Beta1.34
52w lowhigh18.2% off high

What Align Technology does

Maker of Invisalign clear dental aligners and iTero intraoral scanners for orthodontic and general dentistry practices.

Earns a fee for each set of custom aligners shipped to a dental practice, so revenue follows the number of cases and the price per case. Scanners sold to practices feed digital scans into the Invisalign workflow, which brings in more cases. Align makes each patient's aligners in its own plants, mainly in Mexico.

Products and services

  • Invisalign clear aligners
  • iTero intraoral scanners
  • exocad dental CAD/CAM software

Customers

  • Orthodontists
  • General dentists

Where it sits in the supply chain

  • Healthcare
  • Dental/orthodontic devices
  • Clear aligners and digital scanning

What could go right

  • Teen/adult case volume growth
  • International (China, emerging markets) expansion

What could go wrong

  • Patent-expiry-driven generic aligner competition
  • Consumer discretionary spending sensitivity

Moat: narrow (brand, installed base, switching costs). Strong consumer brand and iTero scanner installed base drive doctor loyalty, though core patents have expired.

Headquarters: Tempe, Arizona, USA · Founded: 1997 · Employees: 20,290

Named competitors

Align Technology at a glance

Size Align Technology (ALGN) is a United States Health Care company (Medical Specialties) with a market value of $11.6B, the 707th largest of 3,085 United States companies the cockpit tracks. Shares closed at $163.96 on 18 Nov 2026.

Performance Over six months the shares gained 0.3%, against +27.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 4.4% over the last twelve months (peer median +6.5%); the operating margin is 19.4% (peer median 14.4%).

Valuation It trades at 13.8× forward earnings against a peer median of 20.6× (4th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.7 points above its cost of capital (13.6% WACC).

Backlog Backlog (remaining performance obligations) was $1.35B at 31 Dec 2025, down 6% on a year earlier — 0.3 years of trailing revenue. Backlog detail →

Short interest Short interest is 5.8% of the free float (30 Oct 2026).

Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 127ALGN 101
Six months, rebased to 100: Align Technology against the median of its 20 peers (local-currency closes).

Align Technology financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$4.16B$4.03B$4.00B$3.86B$3.73B
Revenue growth—+1%+4%+3%—
Gross profit$2.97B$2.82B$2.82B$2.73B$2.65B
EBITDA$980M$851M$817M$799M$810M
Net income$492M$410M$421M$445M$362M
Free cash flow$602M$491M$623M$608M$277M
Capital expenditure$147M$102M$116M$178M$292M
Total debt$146M$114M$119M$127M$127M

Quarterly statements and history in the cockpit →

Align Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%COOBIMSNPEN7733AVTRDEMANTQGENBIOBAXLENSKARTPODDGKOSBRKRGMED68827177016869COLO-BRVTYALGN6-month return →1-month return →
Up and to the right = strong over both horizons. Align Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%50×100×COOBIMSNPEN7733DEMANTQGENBIOLENSKARTPODDGKOSBRKRGMED6882716869ALGNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Align Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%COOBIMSNPEN7733AVTRDEMANTQGENBIOBAXLENSKARTPODDBRKRGMEDCOLO-BRVTYALGNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Align Technology is the large dot.

Align Technology competitors and peer comparison

Head to head with its named competitors (ALGN vs STMN.SW vs SOLV vs 6699.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Align Technology ALGN$11.6B0%+4%19%13.8×13.1%
Straumann STMN.SW$20.4B+20%+2%21%32.9×16.2%
Solventum SOLV$14.7B+14%-3%8%11.7×n/a
Angelalign Technology 6699.HK$1.62B-8%+84%9%52.5×16.7%

How Align Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Align Technology against its 20 peers (data as of 18 Nov 2026)
MeasureALGNPeer medianRank in peer set
1-month return+8.9%+4.2%5th highest of 21
6-month return+0.3%+27.4%5th lowest of 21
Distance from 52-week high-18.2%-12.4%7th lowest of 21
Revenue growth (TTM)+4.4%+6.5%8th lowest of 21
Operating margin19.4%14.4%4th highest of 21
Forward P/E13.8×20.6×4th cheapest of 21
Growth the price implies (Req g, 7 yrs)13.1%10.0%8th most demanding of 19
Growth delivered (Del g)+10.3%+7.8%8th highest of 19
Hurdle (Req g minus delivered)+2.9 pp+4.3 pp9th least demanding of 19
ROIC minus cost of capital+5.7 pp+2.3 pp4th highest of 21
EV / EBITDA10.8×13.4×4th cheapest of 19
Net debt / EBITDA-1.0×0.9×2nd least indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%

Align Technology backlog

Align Technology reported $1.35B of remaining performance obligations at 31 Dec 2025, down 6% from a year earlier. That is 0.3 years of trailing revenue already under contract.

Questions

Who are Align Technology's main competitors?
Named competitors: Straumann Group (STMN.SW), Solventum (clear aligners) (SOLV), Angelalign Technology (6699.HK). The cockpit's measured peer set (industry) also includes Cooper Companies (The) (COO), bioMerieux (BIM.PA), Smith & Nephew (SN..L), Penumbra (PEN), Olympus (7733.T), Avantor (AVTR).
Is Align Technology expensive compared with its peers?
On forward p/e it trades at 13.8× against a peer median of 20.6×, 4th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Align Technology stock performed?
Over six months to 18 Nov 2026 the shares returned +0.3% against +27.4% for the median peer; over one year +23.6%.
What is Align Technology's backlog?
Align Technology's remaining performance obligations (contracted revenue not yet recognised) were $1.35B at 31 Dec 2025, -6% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.